U.S. Joint Pain Injections Market Size, Share & Industry Analysis, By Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet Rich Plasma Injections, and Others), By Joint Type (Knee, Hip, Hand & Wrist, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2025-2032

The U.S. joint pain injections market size was valued at USD 2.32 billion in 2024. The market is projected to grow from USD 2.51 billion in 2025 to USD 4.76 billion by 2032, exhibiting a CAGR of 9.58% during the forecast period.

The joint pain injections market is witnessing a noteworthy growth trajectory during the forecast period. Joint pain injections are primarily given intra-articular at the site of the joint to reduce pain. It is used for pain in the knee, hip, hand & wrist, and the shoulder joints.

The surging prevalence of osteoarthritis, rheumatoid arthritis, and geriatric population in the country, along with the presence of a wide range of injectables for treatment, is expected to bolster market growth. The increased awareness of the conditions and improved diagnosis rate in the country supports the market’s growth of joint pain injections and therapies.

• For instance, in March 2025, SEIKAGAKU CORPORATION received from the U.S. Food and Drug Administration (FDA) a complete response letter (CRL) biologics license application (BLA) in the U.S. for SI-6603 condoliase. This treatment reduces leg pain associated with lumbar disc herniation.

Additionally, key players in the joint pain injections market, such as Sanofi, Bioventus Inc., Teva Pharmaceutical Industries Ltd., and others, offer prominent products and engage in strategic activities to support their dominance in the market.

MARKET DYNAMICS

MARKET DRIVERS

Strong Prevalence of Osteoarthritis to Boosts Market Demand

The rising prevalence of osteoarthritis leading to joint pain is one of the most prominent driving factors of the market. Rising aging populations, lifestyle modification leading to increased risk of obesity and musculoskeletal disorders. Thus, joint pain injections reduce the need for surgery and decrease the pain associated with it.  Additionally, the increasing prevalence of joint pain in females and males aged 45 and older is boosting the demand for these products. 

• For instance, according to the Centers for Disease Control and Prevention, in 2022, the prevalence of diagnosed arthritis among U.S. adults aged 18 and older was 18.9%. In which around 21.5% of women were more likely to have arthritis than men at 16.1%. The high number of cases increases demand for products, thereby propelling the U.S. joint pain injections market growth.

MARKET RESTRAINTS

Availability of Alternative Treatment to Hinder Market Growth

The availability of easy-to-use and non-invasive oral drugs such as NSAIDs, oral corticosteroids, and other pain relievers is shifting the focus of patients and practitioners toward these products for joint pain treatment. Thus, such factors are decreasing the adoption of injections and restricting the market growth.

Additionally, increasing approval and product launches for oral pain management drugs to hinder the adoption of joint pain injections.

• For instance, in January 2025, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration had approved Journavx (suzetrigine) 50 milligram oral tablets, a non-opioid analgesic, for the treatment of moderate to severe acute pain in adults.

MARKET OPPORTUNITIES

Integration of New Technologically Advanced Products in Joint Pain Management to Create an Opportunity

Currently available corticosteroids or hyaluronic acid injections offer temporary symptom relief and often require repeated injections. Thus, companies are focusing on developing and launching long-lasting symptom relief injections with a non-opioid mechanism is one of the major factors offering lucrative growth opportunities in the market. The liposome-based product closely mimics natural synovial fluid, thus providing superior lubrication and reducing joint friction, and is more effective than traditional HA injections.

• For instance, in September 2024, Sun Pharmaceuticals Industries Limited and Moebius Medical Limited announced that the U.S. Food and Drug Administration (FDA) had granted a Fast Track designation (FTD) to MM-II (large liposomes of DPPC and DMPC). It is a novel non-opioid suspension for the treatment of osteoarthritis knee pain.

JOINT PAIN INJECTIONS MARKET TRENDS

Increasing Investment and Funding Activities to Support Market Growth

The increasing prevalence of joint pain in the U.S. and rising complications associated with traditional drugs have shifted the focus of key players and emerging players to develop and launch technologically advanced products, which is a significant U.S. joint pain injections market trend. Thus, for this development, the rising trend of fundraising activities and investments in ongoing clinical trials is currently a notable feature in joint pain management.

• For instance, in January 2025, Doron Therapeutics raised USD 11.0 million in funds to initiate Phase 3 clinical studies with MOTYS. MOTYS is an intra-articular placental tissue-derived therapy developed for the management of symptomatic knee osteoarthritis.

Additionally, there are several ongoing clinical trials for various stem cell therapies to treat joint pain, which is currently a trend for joint pain management.

MARKET CHALLENGES

Complications Associated with Joint Pain Injections to Impede Adoption and Market Growth

The complications associated with joint pain injections due to long-term use may pose short-term or long-term complications for the patients. These include intense pain and swelling at the site of injection, stress fractures, pseudo septic reaction, septic arthritis, and even collapse of joints and others. Such factors decrease the trust of patients and practitioners in the adoption of the injections and challenge market growth.

• For instance, in March 2025, a study published in the Cartilage journal found that intra-articular hyaluronic acid injections used for osteoarthritis lead to the risk of complications, such as severe acute localized reactions (SALR).

Download Free sample to learn more about this report.

Segmentation Analysis

By Product

Increasing Approvals and Insurance Coverage for HA Injections Boosted Segment’s Growth

Based on product, the market is segmented into corticosteroid injections, hyaluronic acid injections, platelet rich plasma injections, and others. 

To know how our report can help streamline your business, Speak to Analyst

The hyaluronic acid injections segment held the largest U.S. joint pain injections market share in 2024. The dominant share of the segment is attributed to the increasing prevalence of osteoarthritis in the U.S. and the clinical benefits offered by hyaluronic acid injections, resulting in a growing demand and adoption of these products among patients suffering from osteoarthritis. Additionally, increasing collaborations among key players to offer adequate coverage for better patient outcomes is propelling the segment’s growth in the market.

• For instance, in December 2023, Bioventus Inc. signed a U.S. contract with Aetna Medicare Advantage plans to offer DUROLANE to plan members as an advantage for treating knee osteoarthritis (OA) pain.

By Joint Type

Rising Prevalence of Knee Pain to Bolstered Segment’s Dominance

In terms of joint type, the market is categorized into knee, hip, hand & wrist, and others.

The knee segment accounted for the largest market share. In 2025, the segment is anticipated to dominate with a 43.5% share. The dominant share of the segment is attributed to the increasing number of people in the country with knee pain.

• For instance, according to the Knee Pain Centers of America in the U.S., approximately 25.0% of adults over the age of 45 experience frequent knee pain in February 2025.

The hip segment is expected to grow at a CAGR of 8.74% over the forecast period. 

By Distribution Channel

Increasing Number of Retail Pharmacies Boosted Distribution and Growth

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

In 2024, the retail pharmacies segment dominated the market share. The segment is set to hold 80.7% share in 2025.  The increasing distribution of joint pain injections through retail channels, driven by convenience and the rising number of retail pharmacies in the country, is expected to boost the segment’s growth in the market.

• According to a report published in the December 2022 issue of the Journal of the American Pharmacists Association, there were approximately 61,715 pharmacies nationwide. Of these, about 37,954 (61.5%) were chain pharmacies, 23,521 (38.1%) were regional franchises or independently owned pharmacies, and 240 (0.4%) were government-operated pharmacies.

Additionally, hospital pharmacies are projected to grow as an end-user at a CAGR of 7.81% during the study period.

COMPETITIVE LANDSCAPE

Expansion of Product Offering and Strong Initiatives to Maintain their Market Position

The U.S. joint pain injections market exhibits a fragmented competitive structure, with several players operating with a wide product portfolio and strong presence in the U.S.

Sanofi held a dominant share in terms of competition in the market, attributed to the company’s strong presence and robust product offerings, which helped maintain its position in the market. Furthermore, Bioventus Inc., Zimmer Biomet, Ferring, and Dr. Reddy’s Laboratories Ltd. offer a comprehensive, strong, and advanced product, with a strong focus on research and development activities.

The other players, including Pacira and Anika Therapeutics, Inc., along with others, held a vast share of the U.S. market with their product portfolios of corticosteroid injections and hyaluronic acid injections.

LIST OF KEY JOINT PAIN INJECTIONS COMPANIES PROFILED:

• Reddy’s Laboratories Ltd. (India)
• Sanofi (France)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Zimmer Biomet (S.)
  • Anika Therapeutics, Inc. (S.)
  • Ferring (Switzerland)
  • Bioventus Inc. (S.)
  • SEIKAGAKU CORPORATION (Japan)
  • Pacira Pharmaceuticals, Inc. (S.)
  • Fidia Farmaceutici S.p.A. (Italy)

KEY INDUSTRY DEVELOPMENTS

• July 2025: Thermo Fisher Scientific Inc. partnered with Sanofi to bolster U.S. drug product manufacturing. The partnership aims to expand the site’s operations and meet increasing demand from pharmaceutical and biotech clients for U.S. manufacturing capacity.
• July 2025: Avanos Medical, Inc. sold its Hyaluronic Acid (HA) product line, including TriVisc and GenVisc 850 injections for knee osteoarthritis, to Channel-Markers Medical, LLC.
• May 2025: Genascence Corporation announced positive 12-month safety and biomarker results from its Phase 1b DONATELLO trial of GNSC-001, a gene therapy targeting interleukin 1 for knee osteoarthritis.
• May 2024: Brixton Biosciences has announced the completion of a USD 33.0 million Series B funding round. These funds were used for clinical studies targeting knee pain related to osteoarthritis and to expand the use of its Neural Ice platform beyond the knee to other pain indications with a long-acting, drug-free nerve block.
• November 2023: Teva Pharmaceuticals Industries Ltd. announced the approval of a generic version of Forteo in the U.S. for the treatment of osteoporosis.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation